Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Health Reform Takes Final Shape, Pharma Provisions Still In Play

Executive Summary

Even as news that a breakthrough on one of the major issues separating the House and Senate health care reform bills - taxing high-cost health care plans -emerged near the end of the week of Jan. 11, issues of keen interest for biopharma stakeholders remained unsettled

You may also be interested in...

Chart: Health Care Reform: A Comparison Of The Senate And House Bills

Killing Part D Rebates For Duals Could Cost Pharma Another $12 Billion

As health care reform approaches a House-Senate conference, there is speculation that pharma will commit more money in order to keep the door closed on broader rebates.

Senators Consider Fees On PBMs To Help Close Donut Hole

Pharmacy benefit management companies are objecting to an idea that an annual fee on PBMs could be levied to go towards eliminating the Medicare Part D gap in drug coverage.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts